Capforce Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Capforce Inc (CFOR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Capforce Inc vs Its Competitors
- Growth: Capforce Inc generated 1,150.0% revenue growth year over year in Q2 2026, vs 10.3% for its tracked competitors combined.
- Profitability: Its 84.9% net margin compares with 6.7% for the peer group.
- Peer revenue share: Capforce Inc accounted for 1.3% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CFOR Sales vs. its Competitors, Q2 2026
Capforce Inc reported revenue growth of 1,150.00 % year on year in Q2 2026, above its competitors' combined revenue growth of 10.28 %.
With a net margin of 84.94 %, Capforce Inc achieved higher profitability than its competitors (6.74 %).
Capforce Inc generated 1.29 % of the combined sales of its peer group, up from 0.12 % a year earlier.
Capforce Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Capforce Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Capforce Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Capforce Inc's competitor groups requires a Commercial License.
For context: the Medical Laboratories industry grew revenue 5.7% year over year, combined, vs 1,150.0% for Capforce Inc. Capforce Inc's share of combined industry revenue moved from 0.01% to 0.09%, a gain of 0.08 percentage points.
Capforce Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Capforce Inc | - | - | - | - |
| Competitors combined (12) | ||||
| High-Confidence Competitors (6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CFOR Stock Performance relative to its Competitors
CFOR Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Guardant Health Inc | 282.9% | Outperformed |
| 2 | Illumina Inc | 282.9% | Outperformed |
| 3 | Personalis Inc | 282.9% | Outperformed |
| 4 | Natera Inc | 282.9% | Outperformed |
| 5 | Exact Sciences Corporation | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Capforce Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Capforce Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Capforce Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Capforce Inc | 49.96 | - |
| Natera Inc | 58,997.99 | 2,707.08 |
| Illumina Inc | 41,600.70 | 4,493.00 |
| Guardant Health Inc | 23,561.31 | 1,183.11 |
| Exact Sciences Corporation | 19,599.02 | 3,245.31 |
| Bio rad Laboratories Inc | 10,127.38 | 2,589.00 |
| SUBTOTAL | 158,512.50 | 18,036.63 |
Sign in to see all competitors of Capforce Inc .
Sources: Capforce Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Capforce Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Capforce Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| bioMérieux | Named by the company | 85% |
| Qiagen | Named by the company | 85% |
| Accelerate Diagnostics | Named by the company | 85% |
| Luminex | Named by the company | 85% |
| Cepheid | Named by the company | 85% |
| Roche | Named by the company | 85% |
| Becton-Dickinson | Named by the company | 85% |
| OpGen | Named by the company | 85% |
| GenMark | Named by the company | 85% |
| T2 Biosystems | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Capforce Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Capforce Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Natera Inc | Reportable 100.00 % |
| Illumina Inc | Sequencing 90.94 % |
| Guardant Health Inc | Reportable 100.00 % |
| Bio rad Laboratories Inc | Clinical Diagnostics 59.70 % |
| Fortrea Holdings Inc | Clinical Services 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Capforce Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Capforce Inc | 50 | - | - |
| Natera Inc | 58,998 | 440,892 | -31,327 |
| Illumina Inc | 41,601 | 3,510,156 | 644,531 |
| Guardant Health Inc | 23,561 | 472,109 | -180,940 |
| Exact Sciences Corporation | 19,599 | 450,738 | -28,882 |
| Bio rad Laboratories Inc | 10,127 | 347,517 | 29,852 |
| PEERS TOTAL | 158,463 | 421,998 | -6,417 |
Capforce Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Capforce Inc | International 100.00 % |
| Natera Inc | United States 98.24 % |
| Illumina Inc | United States and Canada 56.34 % |
| Guardant Health Inc | United States 94.35 % |
| Exact Sciences Corporation | United States 93.11 % |
| Bio rad Laboratories Inc | UNITED STATES 40.98 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Capforce Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 42 companies in Capforce Inc's industry classification, broader than the peer set above. Market cap in millions of $.Capforce Inc ranks #0 of 42 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 859, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Natera Inc | 58,998 | 16.87 % |
| 2 | Iqvia Holdings Inc | 46,011 | 13.16 % |
| 3 | Ge Healthcare Technologies Inc | 30,518 | 8.73 % |
| 4 | Quest Diagnostics Inc | 26,613 | 7.61 % |
| 5 | Incyte Corporation | 1,234 | 5.2% |
| 6 | Labcorp Holdings Inc | 1,234 | 5.2% |
| 7 | Guardant Health Inc | 1,234 | 5.2% |
| 8 | Koninklijke Philips Nv | 1,234 | 5.2% |
| 9 | Medpace Holdings Inc | 1,234 | 5.2% |
| 10 | Charles River Laboratories International inc | 1,234 | 5.2% |
| 0 | Capforce Inc | 48 | 0.00 % |
Market cap and industry share for the rest of Capforce Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Capforce Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Laboratories industry average (58 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 1.3x | 37.0x | -35.6x |
| EV / EBITDA | 1.4x | 18.0x | -16.6x |
| P/B | 2.4x | 2.9x | -0.5x |
| Return on Equity | 168.50 % | industry aggregate | 165.53 % |
| Return on Invested Capital | - | -4.04 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Capforce Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue Growth | -20.24 % | -6.88 % | 17.01 % | 31.11 % | - | - |
| Operating Margin | -475.42 % | -442.79 % | -350.75 % | -899.53 % | - | - |
| Return on Invested Capital | -601.17 % | -104.48 % | -198.22 % | -553.27 % | -7.94 % | - |
| P/E | - | - | - | - | 1.1x | 5.0x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Capforce Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 859 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Capforce Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Capforce Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Capforce Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 165.5 points above the industry aggregate.
Weaknesses
No rule matched.
Opportunities
- A meaningful share of tracked competitors (33.30 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Capforce Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Capforce Inc | 0.05 | 2.64 | - |
| Natera Inc | - | 3.14 | 0.05 |
| Illumina Inc | - | 1.74 | 0.75 |
| Guardant Health Inc | 2.56 | 4.29 | - |
| Exact Sciences Corporation | 1.22 | 2.68 | 0.95 |
| Bio rad Laboratories Inc | 0.67 | 4.01 | 0.20 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Capforce Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Capforce Inc | Q2 2026 | +1,150.0 % | +1,117.3 % |
| Natera Inc | Q2 2026 | +37.7 % | - |
| Illumina Inc | Q2 2026 | +9.4 % | -11.9 % |
| Guardant Health Inc | Q2 2026 | +44.3 % | - |
| Exact Sciences Corporation | Q4 2025 | +23.1 % | - |
| Bio rad Laboratories Inc | Q2 2026 | 0.0 % | +16.9 % |
| PEERS TOTAL | +13.4 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Capforce Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Capforce Inc | Q2 2026 | - | - |
| Natera Inc | Q2 2026 | -99.3 % | +144.9 % |
| Illumina Inc | Q2 2026 | +6.9 % | +33.3 % |
| Guardant Health Inc | Q2 2026 | +42.8 % | +108.2 % |
| Exact Sciences Corporation | Q4 2025 | +19.5 % | - |
| Bio rad Laboratories Inc | Q2 2026 | -0.3 % | -30.0 % |
Capforce Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Capforce Inc | 141.40% | 161.42% | 168.50% |
| Natera Inc | - | - | - |
| Illumina Inc | 12.68% | 19.61% | 31.08% |
| Guardant Health Inc | - | - | - |
| Exact Sciences Corporation | - | - | - |
| Bio rad Laboratories Inc | 2.21% | 2.34% | 3.15% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Capforce Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Capforce Inc | 0.75 | - |
| Natera Inc | - | 21.79 |
| Illumina Inc | 50.92 | 9.26 |
| Guardant Health Inc | - | 19.91 |
| Exact Sciences Corporation | - | 6.04 |
| Bio rad Laboratories Inc | 47.27 | 3.91 |
| PEERS AVERAGE | - | 8.79 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.